Huang, Lanxiang
Rong, Yuan
Tang, Xuan
Yi, Kezhen
Qi, Peng
Hou, Jinxuan
Liu, Weihuang
He, Yuan
Gao, Xing
Yuan, Chunhui
Wang, Fubing
Funding for this research was provided by:
Improvement Project for Theranostic ability on Difficulty Miscellaneous disease (Tumor) and the research fund from medical Sci-Tech innovation platform of Zhongnan Hospital (ZLYNXM202008, PTXM2021001)
Article History
Received: 22 November 2021
Accepted: 19 January 2022
First Online: 11 February 2022
Declarations
:
: This research was conducted in accordance with international guidelines and the ethical standards outlined in the Declaration of Helsinki. This study was approved by the Medical Ethics Committee of Zhongnan Hospital of Wuhan University (No. 2021052) and written informed consent was obtained from each patient for the use of their tissue/PBMCs samples. All animal experiments were conducted in compliance with the institutional guidelines of the Animal Experiment Center of University/Animal Biosafety Level-III laboratory for the Use of Animals. All animal procedures were approved by the Experimental Animal Welfare Ethics Committee of Zhongnan Hospital of Wuhan University.
: All authors give consent for the publication of the manuscript in Molecular Cancer.
: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.